Clinical genetic testing adoption across China's extensive hospital network is approaching what many industry observers characterize as an inflection point in 2026, as oncology genomic profiling, reproductive genetic testing, rare disease genetic diagnosis, and pharmacogenomic testing transition from specialized academic medical center services to mainstream clinical tools deployed across...